OBJECTIVE: To investigate whether a probiotic supplementation to cART patients modifies the cerebrospinal fluid (CSF) proteome and improves neurocognitive impairment. METHODS: 26 CSF samples from 13 HIV-positive patients [six patients living with HIV (PLHIV) and seven patients with a history of AIDS (PHAIDS)] were analyzed. All patients underwent to neurocognitive evaluation and blood sampling at baseline and after 6 months of oral bacteriotherapy. Immune phenotyping and activation markers (CD38 and HLA-DR) were evaluated on peripheral blood mononuclear cells (PBMC). Plasma levels of IL-6, sCD14, and MIP-1β were detected, by enzyme-linked immunosorbent assay (ELISA). Functional proteomic analysis of CSF sample was conducted by two-dimensional electrophoresis; a multivariate analysis was performed by principal component analysis (PCA) and data were enriched by STRING software. RESULTS: Oral bacteriotherapy leads to an improvement on several cognitive test and neurocognitive performance in both groups of HIV-positive subjects. A reduction in the percentage of CD4+CD38+HLA-DR+ T cells was also observed at peripheral level after the probiotic intake (p = 0.008). In addition, the probiotic supplementation to cART significantly modifies protein species composition and abundance at the CSF level, especially those related to inflammation (β2-microglobulin p = 0.03; haptoglobin p = 0.06; albumin p = 0.003; hemoglobin p = 0.003; immunoglobulin heavy chains constant region p = 0.02, transthyretin p = 0.02) in PLHIV and PHAIDS. CONCLUSIONS: Our results suggest that oral bacteriotherapy as a supplement to cART could exert a role in the amelioration of inflammation state at peripheral and CNS level.
OBJECTIVE: To investigate whether a probiotic supplementation to cART patients modifies the cerebrospinal fluid (CSF) proteome and improves neurocognitive impairment. METHODS: 26 CSF samples from 13 HIV-positivepatients [six patients living with HIV (PLHIV) and seven patients with a history of AIDS (PHAIDS)] were analyzed. All patients underwent to neurocognitive evaluation and blood sampling at baseline and after 6 months of oral bacteriotherapy. Immune phenotyping and activation markers (CD38 and HLA-DR) were evaluated on peripheral blood mononuclear cells (PBMC). Plasma levels of IL-6, sCD14, and MIP-1β were detected, by enzyme-linked immunosorbent assay (ELISA). Functional proteomic analysis of CSF sample was conducted by two-dimensional electrophoresis; a multivariate analysis was performed by principal component analysis (PCA) and data were enriched by STRING software. RESULTS: Oral bacteriotherapy leads to an improvement on several cognitive test and neurocognitive performance in both groups of HIV-positive subjects. A reduction in the percentage of CD4+CD38+HLA-DR+ T cells was also observed at peripheral level after the probiotic intake (p = 0.008). In addition, the probiotic supplementation to cART significantly modifies protein species composition and abundance at the CSF level, especially those related to inflammation (β2-microglobulin p = 0.03; haptoglobin p = 0.06; albumin p = 0.003; hemoglobin p = 0.003; immunoglobulin heavy chains constant region p = 0.02, transthyretin p = 0.02) in PLHIV and PHAIDS. CONCLUSIONS: Our results suggest that oral bacteriotherapy as a supplement to cART could exert a role in the amelioration of inflammation state at peripheral and CNS level.
Authors: Jaime H Vera; Qi Guo; James H Cole; Adriano Boasso; Louise Greathead; Peter Kelleher; Eugenii A Rabiner; Nicola Kalk; Courtney Bishop; Roger N Gunn; Paul M Matthews; Alan Winston Journal: Neurology Date: 2016-02-24 Impact factor: 9.910
Authors: Jessica A Gold; Marie Grill; Julia Peterson; Christopher Pilcher; Evelyn Lee; Frederick M Hecht; Dietmar Fuchs; Constantin T Yiannoutsos; Richard W Price; Kevin Robertson; Serena Spudich Journal: AIDS Behav Date: 2014-06
Authors: Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price Journal: J Infect Dis Date: 2011-09-01 Impact factor: 5.226
Authors: Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price Journal: BMC Infect Dis Date: 2005-11-02 Impact factor: 3.090
Authors: Samantha J Richardson; Roshen C Wijayagunaratne; Damian G D'Souza; Veerle M Darras; Stijn L J Van Herck Journal: Front Neurosci Date: 2015-03-03 Impact factor: 4.677
Authors: George M Carter; Aryan Esmaeili; Hardikkumar Shah; Debbie Indyk; Matthew Johnson; Michael Andreae; Henry S Sacks Journal: Open Forum Infect Dis Date: 2016-07-29 Impact factor: 3.835
Authors: Sanjay R Mehta; Josué Pérez-Santiago; Todd Hulgan; Tyler R C Day; Jill Barnholtz-Sloan; Haley Gittleman; Scott Letendre; Ronald Ellis; Robert Heaton; Stephanie Patton; Jesse D Suben; Donald Franklin; Debralee Rosario; David B Clifford; Ann C Collier; Christina M Marra; Benjamin B Gelman; Justin McArthur; Allen McCutchan; Susan Morgello; David Simpson; James Connor; Igor Grant; Asha Kallianpur Journal: J Neuroinflammation Date: 2017-03-31 Impact factor: 8.322
Authors: Maike Sperk; Robert van Domselaar; Jimmy Esneider Rodriguez; Flora Mikaeloff; Beatriz Sá Vinhas; Elisa Saccon; Anders Sönnerborg; Kamal Singh; Soham Gupta; Ákos Végvári; Ujjwal Neogi Journal: J Proteome Res Date: 2020-10-23 Impact factor: 4.466